Results

1–8 of 8 results for intravitreal anti-VEGF therapy

Impact of Intravitreal Anti-VEGF Therapy for Severe Non-Proliferative Diabetic Retinopathy (NPDR): Analyses Through a Monte-Carlo Simulation Model
Andrew A. Moshfeghi, MD, MBA, FASRS
On Demand Cases, Courses, and Papers
2021
Intravitreal Anti-VEGF Therapy in Maintaining Long-term Driving Vision in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
Parisa Emami Naeini, MD, MPH, FASRS
Annual Meeting Talks
2021
Assessment of Online Websites Reliability, Content, and Readability for Intravitreal Injections
Nadim M Rayess, MD
On Demand Cases, Courses, and Papers
2020
Cost of Initial Aflibercept, Laser, or Observation in Eyes With Diabetic Macular Edema and Good Vision Based on Management Approaches in Protocol V
Jennifer K. Sun, MD
Annual Meeting Talks
2020
Combination of Dexamethasone Implant and Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration
Raja Narayanan, MD, MBA
Annual Meeting Talks
2020
Predicting Long-term Response to Ranibizumab After Three Injections in Patients With Age-Related Macular Degeneration
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2020
Long-term Clinical Impact of Intravitreal anti-VEGF Therapy for Severe Non-proliferative Diabetic Retinopathy (NPDR): Analyses Through a Discrete Event Simulation Model
Jennifer I. Lim, MD, FARVO, FASRS
Updates from the Field
2021
Episode 125: September 2018 Retinal Physician, Diabetic Retinopathy
Jayanth Sridhar, MD
Member Podcasts
2018